KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Globus Medical (GMED) Shares Outstanding (2016 - 2025)

Globus Medical (GMED) has disclosed Shares Outstanding for 15 consecutive years, with $112.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding rose 400.11% year-over-year to $112.2 million, compared with a TTM value of $112.2 million through Sep 2025, up 400.11%, and an annual FY2024 reading of $22.4 million, changed 0.0% over the prior year.
  • Shares Outstanding was $22.4 million for Q3 2025 at Globus Medical, down from $112.6 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $118.2 million in Q3 2023 and bottomed at $22.4 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $67.9 million, with a median of $77.8 million recorded in 2022.
  • The sharpest move saw Shares Outstanding tumbled 71.62% in 2022, then surged 412.66% in 2024.
  • Year by year, Shares Outstanding stood at $79.1 million in 2021, then decreased by 1.71% to $77.8 million in 2022, then tumbled by 71.16% to $22.4 million in 2023, then soared by 412.66% to $115.0 million in 2024, then decreased by 2.45% to $112.2 million in 2025.
  • Business Quant data shows Shares Outstanding for GMED at $112.2 million in Q3 2025, $112.6 million in Q2 2025, and $22.4 million in Q1 2025.